Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397552 | 0.90 | CCR9 (0.54) | CCR9RAB9AMEN1KMT2APOLB | |
| SCHEMBL3481961 | 0.86 | RAB9A (0.62) | CCR9RAB9AMEN1KMT2APOLB | |
| SCHEMBL3201369 | 0.85 | CCR9 (0.56) | CCR9RAB9AMEN1KMT2APOLB | |
| SCHEMBL14419269 | 0.85 | KCNMA1 (0.60) | CCR9RAB9AMEN1KMT2APOLB | |
| SCHEMBL28077179 | 0.84 | HDAC1 (0.52) | MEN1KMT2APOLBTDP1RECQL | |
| SCHEMBL28060 | 0.83 | RECQL (0.57) | CCR9RAB9AMEN1KMT2APOLB | |
| SCHEMBL31366630 | 0.83 | RECQL (0.57) | CCR9RAB9AMEN1KMT2APOLB | |
| SCHEMBL344032 | 0.82 | RECQL (0.53) | CCR9RAB9AKMT2APOLBSMN1; SMN2 | |
| SCHEMBL3925276 | 0.82 | MAPT (0.67) | RAB9AMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6950942 | 0.81 | GAA (0.65) | RAB9AKMT2APOLBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227409-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227409-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227409-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2021252681-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252681-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| US-6939885-B2 | Aryl sulfonamides | CHEMOCENTRYX (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1562940-A2 | ARYL SULFONAMIDES | ChemoCentryx Inc (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050165067-A1 | Aryl sulfonamides | CHEMOCENTRYX | 2005-07-28 | — | — | US | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885RAB9A 1370/4885MEN1 4867/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885RAB9A 1370/4885MEN1 4867/4885 |
| US-20230227409-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | CCR9 4792/4885RAB9A 953/4885MEN1 1104/4885 |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | EIF4E, EIF4A1, EIF4A2 | CCR9 4805/4885RAB9A 1120/4885MEN1 3781/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | CCR9 4805/4885RAB9A 1120/4885MEN1 3781/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885RAB9A 1370/4885MEN1 4867/4885 |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885RAB9A 871/4885MEN1 3033/4885 |
| US-20050165067-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885RAB9A 1370/4885MEN1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.